LEO Pharma's Tralokinumab Shows Promising Pediatric Safety Data in Phase 2 Trial
Event summary
- LEO Pharma's Phase 2 TRAPEDS-1 trial met primary pharmacokinetic objectives for tralokinumab in children aged 6–11 with moderate-to-severe atopic dermatitis.
- The 172-week study across 11 sites in five countries showed tralokinumab was generally well-tolerated, with safety data consistent with prior adult/adolescent trials.
- Exploratory outcomes included IGA, EASI, SCORAD, and POEM measures to assess treatment impact in this pediatric population.
- Phase 3 TRAPEDS-2 trial is ongoing for children/infants; regulatory approval for ages 6–11 not yet secured.
The big picture
LEO Pharma's positive TRAPEDS-1 results underscore the growing focus on pediatric dermatology, where unmet needs remain substantial. With atopic dermatitis affecting up to 20% of children globally, successful expansion into younger age groups could significantly boost tralokinumab's commercial potential. The trial's long-term design (up to 172 weeks) addresses a critical gap in pediatric drug development, where safety data over extended periods are often limited.
What we're watching
- Regulatory Pathway
- Whether LEO Pharma can secure pediatric approvals for tralokinumab, expanding its addressable market beyond adolescents/adults.
- Competitive Positioning
- How these data position tralokinumab against rivals like dupilumab in the pediatric atopic dermatitis space.
- Long-Term Safety
- The durability of tralokinumab's safety profile over extended use in younger patients, a key concern for clinicians and regulators.